Navigation Links
Two targeted therapies likely better than one in patients with aggressive lymphoma
Date:5/15/2009

ORLANDO - When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).

At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP resulted in an overall 12-month survival of 88 percent in 78 patients. While they call that a very good outcome, the researchers were especially encouraged because the survival rate was 85 percent in patients with high-risk disease.

"These results are very good and very promising, and hopefully will be an important advance over treatment now being offered to patients with this cancer," says the study's lead author, Ivana Micallef, M.D., a Mayo Clinic hematologist. "But we cannot yet say that is so, since the two different regimens haven't been tested head to head."

"Still, we are eager to do a randomized, phase III study because when we compare our results to some other studies of R-CHOP, our findings do look better," she says. In general, those studies showed a 12-month progression-free survival (PFS) of 67 to 79 percent.

The NCCTG multi-institutional research network is planning a clinical trial that will randomize patients with high-risk diffuse large B-cell lymphoma to either this regimen, known as ER-CHOP, or to R-CHOP, the standard treatment. R-CHOP includes a combination of chemotherapy drugs (cyclophosphamide, doxorubicin, and vincristine), the steroid drug prednisone, and rituximab, a monoclonal antibody.

Diffuse large B-cell lymphoma is one of the most common and aggressive forms of non-Hodgkin lymphoma, a cancer of the B-lymphocyte white blood cells.

The researchers are the first to study the addition of epratuzumab to R-CHOP in newly diagnosed, untreated patients. Both epratuzumab and rituximab are monoclonal antibodies that attach to proteins commonly found on the outside surface of B cells CD20 for rituximab and CD22 for epratuzumab. They are also used as immunosuppressive agents to treat certain autoimmune diseases where B cells produce antibodies that attack a person's own cells. "These drugs are designed to shut down B cells, whether they are involved in autoimmunity or are malignant," Dr. Micallef says.

Rituximab is approved for use by the Food and Drug Administration, while epratuzumab is not. That means ER-CHOP treatment cannot be used outside of a clinical trial.

In addition to the results on overall survival, the researchers found an 82 percent progression-free survival in the group. The 39 high-risk patients had a 77 percent PFS, and, for the 39 low-risk patients, PFS was 88 percent. Patients are deemed high risk if they have three or more poor prognostic factors, such as age (60 years or older), elevated LDH (a blood test), advanced disease stage, disease outside of lymph nodes and poor physical performance status.

Dr. Micallef says that the treatment, which is given every 21 days, was well tolerated by patients.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Children who view adult-targeted TV may become sexually active earlier in life
2. Targeted agent shows promise in biliary cancer study
3. Targeted Treatments Show Mettle Against Advanced Cancers
4. UCSF, Stanford Study Reveals Neural Networks Targeted in Brain Diseases
5. Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign
6. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
7. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
8. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
9. Targeted nanospheres find, penetrate, then fuel burning of melanoma
10. Health Integrated Achieves NCQA Full Accreditation for Its Synergy Targeted Population Management(TM) Program
11. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... 2017 , ... Back Pain Centers of America (BPC), which connects ... in their area, announces the launch of a new and proprietary customer relationship management ... for reputable physicians to help them with back or neck pain and helps to ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished ... the Outlier Leadership Series, Outliers in Writing, set to publish in summer 2017. ... Medicine at the University of Arizona College of Medicine. He also serves as Medical ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: